Recent Advances in the Management of Patients with Non-Muscle-Invasive Bladder Cancer Using a Multidisciplinary Approach: Practical Recommendations from the Spanish Oncology Genitourinary (SOGUG) Working Group
Por:
Rubio-Briones, J, Algaba, F, Gallardo, E, Marcos-Rodriguez, JA, Climent, MA, Maroto, P, Arranz Arija, José Ángel
Publicada:
1 oct 2021
Resumen:
Simple Summary:& nbsp;This report presents clinically relevant advances in the management of non-muscle-invasive bladder cancer, which have been the focus of discussion of expert members of the Spanish Oncology Genitourinary (SOGUG) Multidisciplinary Working Group in the framework of the Genitourinary Alliance project (12GU), designed as a space for the integration of novel information in the care of bladder cancer patients. The present study is focused on different aspects regarding the evaluation of hematuria, assessment of second (or repeated) transurethral resection of bladder cancer, histopathological diagnosis and problems with tumor grading, importance of histological variants, shortage of drug supply, and the current role and influence of immunotherapy and biological markers on the oncological outcome of patients. All proposals and recommendations have a multidisciplinary practical approach and are intended to help clinicians in shared decision making for patients with non-muscle-invasive urothelial cancer.
On the basis of the discussion of the current state of research on relevant topics of non-muscle-invasive bladder cancer (NMIBC) among a group of experts of the Spanish Oncology Genitourinary (SOGUG) Working Group, recommendations were proposed to overcome the challenges posed by the management of NMIBC in clinical practice. A unified definition of the term 'microhematuria' and the profile of the patient at risk are needed. Establishing a 'hematuria clinic' would contribute to a centralized and more efficient evaluation of patients with this clinical sign. Second or repeated transurethral resection (re-TUR) needs to be defined, including the time window after the first procedure within which re-TUR should be performed. Complete tumor resection is mandatory when feasible, with specification of the presence or absence of muscle. Budding should be used as a classification system, and stratification of T1 tumors especially in extensive and deep tumors, is advisable. The percentage of the high-grade component should always be reported, and, in multiple tumors, grades should be reported separately. Luminal and basal subtypes can be identified because of possibly different clinical outcomes. Molecular subtypes and immunotherapy are incorporated in the management of muscle-invasive bladder cancer but data on NMIBC are still preliminary.
Filiaciones:
Rubio-Briones, J:
Inst Valenciano Oncol, Urol Dept, Valencia 06009, Spain
Hosp VITHAS 9 Octubre, Valencia 06009, Spain
Algaba, F:
Univ Autonoma Barcelona, Pathol Sect Fundacio Puigvert, Barcelona 08025, Spain
Gallardo, E:
Univ Autonoma Barcelona, Inst Invest Innovac Parc Tauli I3PT, Parc Tauli Hosp Univ, Oncol Dept, Sabadell 08208, Spain
Marcos-Rodriguez, JA:
Hosp Univ Virgen Macarena, Seville 41009, Spain
Climent, MA:
Fdn Inst Valenciano Oncol, Med Oncol Serv, Valencia 46009, Spain
Maroto, P:
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Arranz Arija, José Ángel:
Hospital General Universitario Gregorio Marañón, Madrid, Spain
Green Published, gold
|